Bingliang Fang, M.D., Ph.D.

Peer-Reviewed Articles

1. Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, PDXNET Consortium, EurOPDX Consortium. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 53(1):86-99, 2021. e-Pub 2021. PMID: 33414553.
2. Liu X, Hong L, Nilsson M, Hubert SM, Wu S, Rinsurongkawong W, Lewis J, Spelman A, Roth J, Swisher S, He Y, Jack Lee J, Fang B, Heymach JV, Zhang J, Le X. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer 149:33-40, 2020. e-Pub 2020. PMID: 32956986.
3. Fang B, Meng QH. The laboratory's role in combating COVID-19. Crit Rev Clin Lab Sci 57(6):400-414, 2020. e-Pub 2020. PMID: 32662342.
4. Liu X, Olszewski K, Zhang Y, Lim EW, Shi J, Zhang X, Zhang J, Lee H, Koppula P, Lei G, Zhuang L, You MJ, Fang B, Li W, Metallo CM, Poyurovsky MV, Gan B. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer. Nat Cell Biol 22(4):476-486, 2020. e-Pub 2020. PMID: 32231310.
5. Liu T, Jia P, Fang B, Zhao Z. Differential Expression of Viral Transcripts From Single-Cell RNA Sequencing of Moderate and Severe COVID-19 Patients and Its Implications for Case Severity. Front Microbiol 11:603509, 2020. e-Pub 2020. PMID: 33178176.
6. Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A, Wu S, Meng QH, Ha MJ, Morris J, Xi Y, Wang J, Zhang J, Gibbons DL, Heymach JV, Meric-Bernstam F, Minna J, Swisher SG, Roth JA, Fang B. KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res 10(12):4464-4475, 2020. e-Pub 2020. PMID: 33415011.
7. Meraz IM, Majidi M, Meng F, Shao R, Ha MJ, Neri S, Fang B, Lin SH, Tinkey PT, Shpall EJ, Morris J, Roth JA. An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunol Res 7(8):1267-1279, 2019. e-Pub 2019. PMID: 31186248.
8. Baity M, Wang L, Correa AM, Zhang X, Zhang R, Pataer A, Wu S, Meng QH, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Zhao M, Gu J, Fang B. Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. Am J Cancer Res 9(6):1201-1211, 2019. e-Pub 2019. PMID: 31285952.
9. Chen Y, Zhang R, Wang L, Correa AM, Pataer A, Xu Y, Zhang X, Ren C, Wu S, Meng QH, Fujimoto J, Jensen VB, Antonoff MB, Hofstetter WL, Mehran RJ, Pisimisis G, Rice DC, Sepesi B, Vaporciyan AA, Walsh GL, Swisher SG, Roth JA, Heymach JV, Fang B. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer 125(21):3738-3748, 2019. e-Pub 2019. PMID: 31287557.
10. Pu X, Wu L, Su D, Mao W, Fang B. Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer 18(1):1082, 2018. e-Pub 2018. PMID: 30409126.
11. Pu X, Zhang R, Wang L, Chen Y, Xu Y, Pataer A, Meraz IM, Zhang X, Wu S, Wu L, Su D, Mao W, Heymach JV, Roth JA, Swisher SG, Fang B. Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. J Transl Med 16(1):328, 2018. e-Pub 2018. PMID: 30477533.
12. Hou H, Zhu H, Zhao H, Yan W, Wang Y, Jiang M, Liu B, Liu D, Zhou N, Zhang C, Li P, Chang L, Guan Y, Wang Z, Zhang X, Li Z, Fang B, Zhang X. Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile. Oncologist 23(9):1008-1015, 2018. e-Pub 2018. PMID: 29700208.
13. Goltsov AA, Fang B, Pandita TK, Maru DM, Swisher SG, Hofstetter WL. HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells. Ann Thorac Surg 105(2):363-370, 2018. e-Pub 2017. PMID: 29223420.
14. Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li C, Wang J, Fang B, Wang J, Li L, Badillo M, Ahmed M, Thirumurthi S, Huang SY, Shao Y, Lam L, Yi Q, Wang YL, Wang M. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res 23(15):4212-4223, 2017. e-Pub 2017. PMID: 28348046.
15. Roife D, Kang Y, Wang L, Fang B, Swisher SG, Gershenwald JE, Pretzsch S, Dinney CP, Katz MHG, Fleming JB. Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery 161(5):1246-1254, 2017. e-Pub 2017. PMID: 28081955.
16. Zhou W, Dai S, Zhu H, Song Z, Cai Y, Lee JB, Li Z, Hu X, Fang B, He C, Huang X. Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer. Gene Ther 24(4):199-207, 2017. e-Pub 2017. PMID: 28075429.
17. Yan X, Wang L, Zhang R, Pu X, Wu S, Yu L, Meraz IM, Zhang X, Wang JF, Gibbons DL, Mehran RJ, Swisher SG, Roth JA, Fang B. Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. Oncoimmunology 7(1):e1376156, 2017. e-Pub 2017. PMID: 29296537.
18. Xiaobo C, Majidi M, Feng M, Shao R, Wang J, Zhao Y, Baladandayuthapani V, Song J, Fang B, Ji L, Mehran R, Roth JA. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin. Sci Rep 6:35741, 2016. e-Pub 2016. PMID: 27845352.
19. White L, Wu S, Ma J, Fang B, Liang D. Simultaneous determination and validation of oncrasin-266 and its metabolites by HPLC-MS/MS: Application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 1033-1034:106-111, 2016. e-Pub 2016. PMID: 27541624.
20. Yan X, Fang B. Harnessing plasma genotyping for precision therapy against lung cancer. J Thorac Dis 8(10):E1387-E1390, 2016. PMID: 27867637.
21. Li H, Hu J, Wu S, Wang L, Cao X, Zhang X, Dai B, Cao M, Shao R, Zhang R, Majidi M, Ji L, Heymach JV, Wang M, Pan S, Minna J, Mehran RJ, Swisher SG, Roth JA, Fang B. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget 7(3):3548-58, 2016. e-Pub 2015. PMID: 26657290.
22. Fang B. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. Acta Biochem Biophys Sin (Shanghai) 48(1):27-38, 2016. e-Pub 2015. PMID: 26350096.
23. Wu S, Wang L, Huang X, Cao M, Hu J, Li H, Zhang H, Sun X, Meng QH, Hofstetter WL, Roth JA, Swisher SG, Fang B. Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380. Bioorg Med Chem 22(19):5234-40, 2014. e-Pub 2014. PMID: 25182964.
24. Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B. Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-Small Cell Lung Cancer Cells. J Natl Cancer Inst 106(9), 2014. e-Pub 2014. PMID: 25214559.
25. Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG, University of Texas MD Anderson Lung Cancer Collaborative Group [Fang B]. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15(1):e42-50, 2014. PMID: 24384493.
26. Ji H, Wang J, Fang B, Fang X, Lu Z. a-Catenin inhibits glioma cell migration, invasion, and proliferation by suppression of ß-catenin transactivation. J Neurooncol 103(3):445-51, 2011. e-Pub 2010. PMID: 20872274.
27. Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD, Fang B, Roth JA. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res 71(10):3658-68, 2011. e-Pub 2011. PMID: 21444672.
28. Wu S, Wang L, Guo W, Liu X, Liu J, Wei X, Fang B. Analogues and Derivatives of Oncrasin-1, a Novel Inhibitor of the C-Terminal Domain of RNA Polymerase II and Their Antitumor Activities. J Med Chem 54(8):2668-79, 2011. e-Pub 2011. PMID: 21443218.
29. Guo W, Wei X, Wu S, Wang L, Peng H, Wang J, Fang B. Antagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species. Eur J Pharmacol 649(1-3):51-8, 2010. e-Pub 2010. PMID: 20854805.
30. Pataer A, Raso MG, Correa AM, Behrens C, Tsuta K, Solis L, Fang B, Roth JA, Wistuba II, Swisher SG. Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res 16(22):5522-8, 2010. e-Pub 2010. PMID: 20930042.
31. Zhou Y, Hofstetter WL, He Y, Hu W, Pataer A, Wang L, Wang J, Zhou Y, Yu L, Fang B, Swisher SG. KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression. Cancer Biol Ther 9(7):507-13, 2010. e-Pub 2010. PMID: 20215880.
32. Ziauddin MF, Guo ZS, O'Malley ME, Austin F, Popovic PJ, Kavanagh MA, Li J, Sathaiah M, Thirunavukarasu P, Fang B, Lee YJ, Bartlett DL. TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther 17(4):550-9, 2010. e-Pub 2010. PMID: 20182517.
33. Wei X, Guo W, Wu S, Wang L, Huang P, Liu J, Fang B. Oxidative stress in NSC-741909-induced apoptosis of cancer cells. J Transl Med 8:37, 2010. e-Pub 2010. PMID: 20398386.
34. Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS One 5(9):e13026, 2010. e-Pub 2010. PMID: 20885957.
35. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 5(11):e14124, 2010. e-Pub 2010. PMID: 21124782.
36. Meng J, Peng H, Dai B, Guo W, Wang L, Ji L, Minna JD, Chresta CM, Smith PD, Fang B, Roth JA. High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther 8(21):2073-80, 2009. e-Pub 2009. PMID: 19783898.
37. Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q, Fang B, Fang X, Fang D, Litchfield DW, Aldape K, Lu Z. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell 36(4):547-59, 2009. PMID: 19941816.
38. Hu W, Hofstetter WL, Li H, Zhou Y, He Y, Pataer A, Wang L, Xie K, Swisher SG, Fang B. Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma. Clin Cancer Res 15(18):5688-95, 2009. e-Pub 2009. PMID: 19737957.
39. Wei X, Guo W, Wu S, Wang L, Lu Y, Xu B, Liu J, Fang B. Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells. J Biol Chem 284(25):16948-55, 2009. e-Pub 2009. PMID: 19414586.
40. Guo W, Wu S, Wang L, Wang RY, Wei X, Liu J, Fang B. Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). Mol Cancer Ther 8(2):441-8, 2009. e-Pub 2009. PMID: 19208825.
41. Guo W, Wu S, Liu J, Fang B. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res 68(18):7403-8, 2008. PMID: 18794128.
42. Hu W, Hofstetter W, Guo W, Li H, Pataer A, Peng HH, Guo ZS, Bartlett DL, Lin A, Swisher SG, Fang B. JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase. Cancer Gene Ther 15(9):616-24, 2008. e-Pub 2008. PMID: 18535619.
43. Shamimi-Noori S, Yeow WS, Ziauddin MF, Xin H, Tran TL, Xie J, Loehfelm A, Patel P, Yang J, Schrump DS, Fang BL, Nguyen DM. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther 15(6):356-70, 2008. e-Pub 2008. PMID: 18309355.
44. Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I. Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther 16(5):886-92, 2008. e-Pub 2008. PMID: 18388920.
45. Wagener M, Zhang X, Villarreal HG, Levy L, Allen P, Shentu S, Fang B, Krishnan S, Chang JY, Cheung MR. Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer. Oncol Rep 19(5):1071-7, 2008. PMID: 18425360.
46. Zhang X, Komaki R, Wang L, Fang B, Chang JY. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 14(9):2813-23, 2008. PMID: 18451249.
47. Zhou H, Wu S, Zhai S, Liu A, Sun Y, Li R, Zhang Y, Ekins S, Swaan PW, Fang B, Zhang B, Yan B. Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem 51(5):1242-51, 2008. e-Pub 2008. PMID: 18257542.
48. Hu W, Davis JJ, Zhu H, Dong F, Guo W, Ang J, Peng H, Guo ZS, Bartlett DL, Swisher SG, Fang B. Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy. Cancer Biol Ther 6(11):1773-9, 2007. e-Pub 2007. PMID: 17986853.
49. Zhu H, Zhu Y, Hu J, Hu W, Liao Y, Zhang J, Wang D, Huang X, Fang B, He C. Adenovirus-mediated small hairpin RNA targeting Bcl-XL as therapy for colon cancer. Int J Cancer 121(6):1366-72, 2007. PMID: 17534896.
50. Deng WG, Nishizaki M, Fang B, Roth JA, Ji L. Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells. Biochem Biophys Res Commun 355(4):993-9, 2007. e-Pub 2007. PMID: 17328863.
51. Hannay J, Davis JJ, Yu D, Liu J, Fang B, Pollock RE, Lev D. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. Gene Ther 14(8):671-81, 2007. e-Pub 2007. PMID: 17287860.
52. Teraishi F, Zhang L, Guo W, Dong F, Davis JJ, Lin A, Fang B. Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells. FEBS Lett 579(29):6681-7, 2005. e-Pub 2005. PMID: 16307741.
53. Teraishi F, Wu S, Sasaki J, Zhang L, Davis JJ, Guo W, Dong F, Fang B. JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells. Cell Mol Life Sci 62(19-20):2382-9, 2005. PMID: 16179969.
54. Zhang X, Cheung RM, Komaki R, Fang B, Chang JY. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer. Clin Cancer Res 11(18):6657-68, 2005. PMID: 16166445.
55. Teraishi F, Wu S, Sasaki J, Zhang L, Zhu HB, Davis JJ, Fang B. P-glycoprotein-independent apoptosis induction by a novel synthetic compound, MMPT [5-[(4-methylphenyl)methylene]-2-(phenylamino)-4(5H)-thiazolone]. J Pharmacol Exp Ther 314(1):355-62, 2005. e-Pub 2005. PMID: 15831436.
56. Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ, Dong F, Fang B. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther 4(7):781-6, 2005. e-Pub 2005. PMID: 16082182.
57. Teraishi F, Wu S, Zhang L, Guo W, Davis JJ, Dong F, Fang B. Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells. Cancer Res 65(14):6380-7, 2005. PMID: 16024641.
58. Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, Davis JJ, Chiao PJ, Fang B. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 24(31):4993-9, 2005. PMID: 15824729.
59. Zhang L, Zhu H, Teraishi F, Davis JJ, Guo W, Fan Z, Fang B. Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia 7(6):594-602, 2005. PMID: 16036110.
60. Pan J, Huang H, Sun L, Fang B, Yeung SC. Bcl-2-associated X protein is the main mediator of manumycin a-induced apoptosis in anaplastic thyroid cancer cells. J Clin Endocrinol Metab 90(6):3583-91, 2005. e-Pub 2005. PMID: 15769983.
61. Jacob D, Schumacher G, Bahra M, Davis J, Zhu HB, Zhang LD, Teraishi F, Neuhaus P, Fang BL. Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells. World J Gastroenterol 11(17):2552-6, 2005. PMID: 15849810.
62. Zhu H, Guo W, Zhang L, Davis JJ, Wu S, Teraishi F, Cao X, Smythe WR, Fang B. Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol Ther 4(4):393-7, 2005. e-Pub 2005. PMID: 15846108.
63. Zhu H, Guo W, Zhang L, Davis JJ, Teraishi F, Wu S, Cao X, Daniel J, Smythe WR, Fang B. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 4(3):451-6, 2005. PMID: 15767554.
64. Jacob D, Davis JJ, Zhang L, Zhu H, Teraishi F, Fang B. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther 12(2):109-15, 2005. PMID: 15486557.
65. Reddy RM, Tsai WS, Ziauddin MF, Zuo J, Cole GW, Maxhimer JB, Fang B, Schrump DS, Nguyen DM. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand. J Thorac Cardiovasc Surg 128(6):883-91, 2004. PMID: 15573073.
66. Jacob D, Davis J, Schumacher G, Bahra M, Neuhaus P, Fang B. [Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter]. Z Gastroenterol 42(12):1363-70, 2004. PMID: 15592959.
67. Han J, Goldstein LA, Gastman BR, Rabinovitz A, Wang GQ, Fang B, Rabinowich H. Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells. Leukemia 18(10):1671-80, 2004. PMID: 15356645.
68. Jacob D, Bahra M, Schumacher G, Neuhaus P, Fang B. Gene therapy in colon cancer cells with a fiber-modified adenovector expressing the TRAIL gene driven by the hTERT promoter. Anticancer Res 24(5A):3075-9, 2004. PMID: 15517918.
69. Nishizaki M, Sasaki J, Fang B, Atkinson EN, Minna JD, Roth JA, Ji L. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res 64(16):5745-52, 2004. PMID: 15313915.
70. Zhu H, Zhang L, Wu S, Teraishi F, Davis JJ, Jacob D, Fang B. Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERK. Oncogene 23(29):4984-92, 2004. PMID: 15122344.
71. Zhu H, Zhang L, Huang X, Davis JJ, Jacob DA, Teraishi F, Chiao P, Fang B. Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther 9(5):666-73, 2004. PMID: 15120327.
72. Jacob D, Davis J, Zhu H, Zhang L, Teraishi F, Wu S, Marini FC, Fang B. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin Cancer Res 10(10):3535-41, 2004. PMID: 15161713.
73. Honda T, Coppola S, Ghibelli L, Cho SH, Kagawa S, Spurgers KB, Brisbay SM, Roth JA, Meyn RE, Fang B, McDonnell TJ. GSH depletion enhances adenoviral bax-induced apoptosis in lung cancer cells. Cancer Gene Ther 11(4):249-55, 2004. PMID: 15002033.
74. Tsunemitsu Y, Kagawa S, Tokunaga N, Otani S, Umeoka T, Roth JA, Fang B, Tanaka N, Fujiwara T. Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut 53(4):554-60, 2004. PMID: 15016751.
75. Zhang L, Zhu H, Davis JJ, Jacob D, Wu S, Teraishi F, Gutierrez A, Wang Y, Fang B. Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. Cancer Biol Ther 3(3):296-301, 2004. e-Pub 2004. PMID: 14749540.
76. He C, Lao WF, Hu XT, Xu XM, Xu J, Fang BL. Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects. World J Gastroenterol 10(5):654-9, 2004. PMID: 14991932.
77. Wu S, Zhu H, Gu J, Zhang L, Teraishi F, Davis JJ, Jacob DA, Fang B. Induction of apoptosis and down-regulation of Bcl-XL in cancer cells by a novel small molecule, 2[[3-(2,3-dichlorophenoxy)propyl]amino]ethanol. Cancer Res 64(3):1110-3, 2004. PMID: 14871845.
78. Gu J, Zhang L, Swisher SG, Liu J, Roth JA, Fang B. Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis. Oncogene 23(6):1300-7, 2004. PMID: 14676844.
79. Lin T, Zhang L, Davis J, Gu J, Nishizaki M, Ji L, Roth JA, Xiong M, Fang B. Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther 8(3):441-8, 2003. PMID: 12946317.
80. Katz MH, Spivack DE, Takimoto S, Fang B, Burton DW, Moossa AR, Hoffman RM, Bouvet M. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Ann Surg Oncol 10(7):762-72, 2003. PMID: 12900367.
81. Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene 22(36):5694-701, 2003. PMID: 12944918.
82. Huang X, Lin T, Gu J, Zhang L, Roth JA, Liu J, Fang B. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. Int J Oncol 22(6):1241-5, 2003. PMID: 12738989.
83. Xu XM, He C, Hu XT, Fang BL. Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29. World J Gastroenterol 9(5):965-9, 2003. PMID: 12717839.
84. Krieg A, Krieg T, Wenzel M, Schmitt M, Ramp U, Fang B, Gabbert HE, Gerharz CD, Mahotka C. TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential. Br J Cancer 88(6):918-27, 2003. PMID: 12644830.
85. Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, Bast RC. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res 62(24):7264-72, 2002. PMID: 12499268.
86. Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M, Curley SA, Yu Y, Hunt KK, Fang B. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 21(52):8020-8, 2002. PMID: 12439752.
87. Huang X, Lin T, Gu J, Zhang L, Roth JA, Stephens LC, Yu Y, Liu J, Fang B. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther 9(20):1379-86, 2002. PMID: 12365003.
88. Zhang L, Gu J, Lin T, Huang X, Roth JA, Fang B. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther 9(18):1262-70, 2002. PMID: 12215894.
89. Pirocanac EC, Nassirpour R, Yang M, Wang J, Nardin SR, Gu J, Fang B, Moossa AR, Hoffman RM, Bouvet M. Bax-induction gene therapy of pancreatic cancer. J Surg Res 106(2):346-51, 2002. PMID: 12175991.
90. Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA, Fang B. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 62(13):3620-5, 2002. PMID: 12097263.
91. Gu J, Zhang L, Huang X, Lin T, Yin M, Xu K, Ji L, Roth JA, Fang B. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 21(31):4757-64, 2002. PMID: 12101414.
92. Tanyi JL, Lapushin R, Eder A, Auersperg N, Tabassam FH, Roth JA, Gu J, Fang B, Mills GB, Wolf J. Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. Gynecol Oncol 85(3):451-8, 2002. PMID: 12051873.
93. Nutt LK, Chandra J, Pataer A, Fang B, Roth JA, Swisher SG, O'Neil RG, McConkey DJ. Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem 277(23):20301-8, 2002. e-Pub 2002. PMID: 11909872.
94. Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C, Xu K, Yen N, Atkinson EN, Fang B, Lerman MI, Roth JA, Minna JD. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 62(9):2715-20, 2002. PMID: 11980673.
95. Nikitina EY, Chada S, Muro-Cacho C, Fang B, Zhang R, Roth JA, Gabrilovich DI. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther 9(5):345-52, 2002. PMID: 11938454.
96. Honda T, Kagawa S, Spurgers KB, Gjertsen BT, Roth JA, Fang B, Lowe SL, Norris JS, Meyn RE, McDonnell TJ. A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity. Cancer Biol Ther 1(2):163-7, 2002. PMID: 12170776.
97. Nutt LK, Pataer A, Pahler J, Fang B, Roth J, McConkey DJ, Swisher SG. Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J Biol Chem 277(11):9219-25, 2002. e-Pub 2001. PMID: 11741880.
98. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 9(1):30-7, 2002. PMID: 11850720.
99. Adachi Y, Chandrasekar N, Kin Y, Lakka SS, Mohanam S, Yanamandra N, Mohan PM, Fuller GN, Fang B, Fueyo J, Dinh DH, Olivero WC, Tamiya T, Ohmoto T, Kyritsis AP, Rao JS. Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences. Oncogene 21(1):87-95, 2002. PMID: 11791179.
100. Li Z, Xia W, Fang B, Yan DH. Targeting HER-2/neu-overexpressing breast cancer cells by an antisense iron responsive element-directed gene expression. Cancer Lett 174(2):151-8, 2001. PMID: 11689290.
101. Wang GQ, Wieckowski E, Goldstein LA, Gastman BR, Rabinovitz A, Gambotto A, Li S, Fang B, Yin XM, Rabinowich H. Resistance to granzyme B-mediated cytochrome c release in Bak-deficient cells. J Exp Med 194(9):1325-37, 2001. PMID: 11696597.
102. Wang GQ, Gastman BR, Wieckowski E, Goldstein LA, Gambotto A, Kim TH, Fang B, Rabinovitz A, Yin XM, Rabinowich H. A role for mitochondrial Bak in apoptotic response to anticancer drugs. J Biol Chem 276(36):34307-17, 2001. e-Pub 2001. PMID: 11447222.
103. Andriani F, Nan B, Yu J, Li X, Weigel NL, McPhaul MJ, Kasper S, Kagawa S, Fang B, Matusik RJ, Denner L, Marcelli M. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst 93(17):1314-24, 2001. PMID: 11535706.
104. Mohiuddin I, Cao X, Fang B, Nishizaki M, Smythe WR. Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. Cancer Gene Ther 8(8):547-54, 2001. PMID: 11571532.
105. Kagawa S, Gu J, Honda T, McDonnell TJ, Swisher SG, Roth JA, Fang B. Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death. Clin Cancer Res 7(5):1474-80, 2001. PMID: 11350920.
106. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC, Fang B. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 61(8):3330-8, 2001. PMID: 11309289.
107. Koch PE, Guo ZS, Kagawa S, Gu J, Roth JA, Fang B. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol Ther 3(3):278-83, 2001. PMID: 11273768.
108. Pataer A, Smythe WR, Yu R, Fang B, McDonnell T, Roth JA, Swisher SG. Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines. J Thorac Cardiovasc Surg 121(1):61-7, 2001. PMID: 11135160.
109. Li X, Marani M, Yu J, Nan B, Roth JA, Kagawa S, Fang B, Denner L, Marcelli M. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer. Cancer Res 61(1):186-91, 2001. PMID: 11196158.
110. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, Fang B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 60(19):5359-64, 2000. PMID: 11034071.
111. Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Ji L, Roth JA, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 19(38):4432-6, 2000. PMID: 10980619.
112. Sueoka N, Lee HY, Walsh GL, Fang B, Ji L, Roth JA, LaPushin R, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-6 inhibits the growth of human bronchial epithelial cells and increases in abundance with all-trans-retinoic acid treatment. Am J Respir Cell Mol Biol 23(3):297-303, 2000. PMID: 10970819.
113. Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R, Pisters KM, Putnam JB, Schrump DS, Shin DM, Walsh GL, Roth JA. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther 7(4):530-6, 2000. PMID: 10811470.
114. Kagawa S, Gu J, Swisher SG, Ji L, Roth JA, Lai D, Stephens LC, Fang B. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res 60(5):1157-61, 2000. PMID: 10728665.
115. Pataer A, Fang B, Yu R, Kagawa S, Hunt KK, McDonnell TJ, Roth JA, Swisher SG. Adenoviral Bak overexpression mediates caspase-dependent tumor killing. Cancer Res 60(4):788-92, 2000. PMID: 10706081.
116. Kagawa S, Pearson SA, Ji L, Xu K, McDonnell TJ, Swisher SG, Roth JA, Fang B. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther 7(1):75-9, 2000. PMID: 10680019.
117. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59(14):3333-9, 1999. PMID: 10416589.
118. Mohan PM, Chintala SK, Mohanam S, Gladson CL, Kim ES, Gokaslan ZL, Lakka SS, Roth JA, Fang B, Sawaya R, Kyritsis AP, Rao JS. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res 59(14):3369-73, 1999. PMID: 10416596.
119. Ji L, Fang B, Roth JA. A rapid, sensitive, and nonradioactive method for assay of FHIT Ap3A hydrolase activity by fluorescence thin-layer chromatographic image analysis. Anal Biochem 271(1):114-6, 1999. PMID: 10361018.
120. Chen YQ, Hsieh JT, Yao F, Fang B, Pong RC, Cipriano SC, Krepulat F. Induction of apoptosis and G2/M cell cycle arrest by DCC. Oncogene 18(17):2747-54, 1999. PMID: 10348349.
121. Ji L, Bouvet M, Price RE, Roth JA, Fang B. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement. Gene Ther 6(3):393-402, 1999. PMID: 10435089.
122. Kagawa S, Pearson SA, Ji L, Xu K, McDonnell TJ, Swisher SG, Fang B, Roth JA. A novel binary vector can mediate expression of the death effector protein bax in human lung cancer cells. Surg Forum L:344-346, 1999.
123. Bouvet M, Bold RJ, Lee J, Evans DB, Abbruzzese JL, Chiao PJ, McConkey DJ, Chandra J, Chada S, Fang B, Roth JA. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. Ann Surg Oncol 5(8):681-8, 1998. PMID: 9869513.
124. Fang B, Xu B, Koch P, Roth JA. Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells. Gene Ther 5(10):1420-4, 1998. PMID: 9930348.
125. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, Fang B, Lee JJ, Roth JA. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 58(11):2288-92, 1998. PMID: 9622060.
126. Bouvet M, Fang B, Ekmekcioglu S, Ji L, Bucana CD, Hamada K, Grimm EA, Roth JA. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther 5(2):189-95, 1998. PMID: 9578838.
127. Fang B, Ji L, Bouvet M, Roth JA. Evaluation of GAL4/TATA in vivo. Induction of transgene expression by adenovirally mediated gene codelivery. J Biol Chem 273(9):4972-5, 1998. PMID: 9478943.
128. Fang B, Ji L, Bouvet M, Roth JA. in vivo: Induction of transgene expression by adenovirally mediated gene codelivery. J Biol Chem 273:4972-4975, 1998.
129. Fang B, Koch P, Bouvet M, Ji L, Roth JA. A packaging system for SV40 vectors without viral coding sequences. Anal Biochem 254(1):139-43, 1997. PMID: 9398356.
130. Fang B, Koch P, Roth JA. Diminishing adenovirus gene expression and viral replication by promoter replacement. J Virol 71(6):4798-803, 1997. PMID: 9151874.
131. Bouvet M, Ellis LM, Liu W, Fang B, Roth JA. Adenovirally mediated wild-type p53 gene therapy downregulates vascular endothelial growth factor expression in human colon cancer. Surg Forum 48:806-809, 1997.
132. Fang B, Wang H, Gordon G, Bellinger DA, Read MS, Brinkhous KM, Woo SL, Eisensmith RC. Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther 3(3):217-22, 1996. PMID: 8646552.
133. Huang S, Li Hui , Miao S, Xu L, Fang B, Liu G, Luo H. [Analysis of the A/C polymorphic site within the phenylalanine hydroxylase gene]. Yi Chuan Xue Bao 23(3):169-73, 1996. PMID: 8950848.
134. Yan F, Huang S, Gao X, Wang M, Fang B, Li H, Luo HY. Confirming the cause of inherited chronic chorea in Chinese patients. Chin Med J 76:197-199, 1996.
135. Yang T, Yuan L, Huang S, Fang B, Wang M, Gu G, Min S, Luo HY. Detection of the mutational gene in Phenylketonuria and prenatal diagnosis by using single strand conformation polymorphism methods. Chin J Obstet Gyne 67:401-403, 1996.
136. Yuan L, Gao Y, Lo S, Fang B, Ye J. [Prediction of retinoblastoma: linkage analysis of families with hereditary retinoblastoma by using polymorphic sites within the Rb gene]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 17(5):338-42, 1995. PMID: 8706167.
137. Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN, Gordon G, Bellinger DA, Read MS, Hu PC. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 6(8):1039-44, 1995. PMID: 7578416.
138. Li J, Fang B, Eisensmith RC, Li XH, Nasonkin I, Lin-Lee YC, Mims MP, Hughes A, Montgomery CD, Roberts JD. In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J Clin Invest 95(2):768-73, 1995. PMID: 7860759.
139. Huang S, Fang B, Chu H. [Analysis of short tandem repeats polymorphism in the phenylalanine hydroxylase gene and its application to prenatal gene diagnosis of phenylketonuria]. Zhonghua Yi Xue Za Zhi 75(1):22-4, 61, 1995. PMID: 7600314.
140. Le H, Xie JY, Fang B, Huang S, Wang M, Shi HP, Tang X, Gao X, Luo HY. Gene diagnosis of Wilson’s disease. Chin J Neurol 28:195-198, 1995.
141. Yuan S, Huang S, Luo HY, Fang B, Wang M, Wang T, Sun G, Zhao M, Liu S, Ye J. Prenatal gene diagnosis of classical phenylketonuria in 16 pregnancies with high risk. Chin J Med Genet 12:327-329, 1995.
142. Song, F, Fang B, Liu J, Luo HY, Wu G. Multiplex allele specific polymerase chain reaction in the diagnosis of phenylketonuria. Chin Sci Bull 39:76-79, 1994.
143. Miao S, Fang B, Huang S, Wang M, Yuan L, Luo HY. Detection of point mutations in exon 7 of phenylalanine hydroxylase gene by PCR-SSCP method. Chin J Med Genet 10:1511-1514, 1993.
144. Fang B, Yuan L, Wang M, Huang S, Wang T, Miao S, Ye J, Sun N, Lo H, Savio LC. Detection of point mutations of the phenylalanine hydroxylase gene and prenatal diagnosis of phenylketonuria. Chin Med Sci J 7(4):205-8, 1992. PMID: 1307495.
145. Fang BL. [Tightly linked DNA probe for presymptomatic diagnosis and carrier detection of Wilson disease]. Zhonghua Yi Xue Za Zhi 72(12):746-8, 774, 1992. PMID: 1363748.
146. Fang B. [Polymorphisms of the D13S26 locus in Chinese and its application to linkage analysis of Wilson disease]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 14(3):206-9, 1992. PMID: 1356645.
147. Fang B. [Analysis of RFLP haplotypes and point mutations at the phenylalanine hydroxylase (PAH) locus in PKU families from north China]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 14(1):46-50, 1992. PMID: 1350519.
148. Goedde HW, Agarwal DP, Fritze G, Meier-Tackmann D, Singh S, Beckmann G, Bhatia K, Chen LZ, Fang B, Lisker R. Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet 88(3):344-6, 1992. PMID: 1733836.
149. Wang T, Yuan L, Fang B, Huang SZ, Luo HY. Prenatal diagnosis of classical phenylketonuria with polymerase chain reaction and allele specific oligonucleotide probe hybridization. Chin J Pediatr 34:341, 1992.
150. Fang B. Restriction fragment length polymorphism (RFLP) analysis (methodology review). Basic Med Sci Clin 11:376-380, 1992.
151. Li,J, Fang B, Liu Y, Luo HY. Isolation of chromosomal sized human and yeast genomic DNA for pulse field electrophoresis. Chin J Med Genet 8:334, 1991.
152. Singh S, Fritze G, Fang BL, Harada S, Paik YK, Eckey R, Agarwal DP, Goedde HW. Inheritance of mitochondrial aldehyde dehydrogenase: genotyping in Chinese, Japanese and South Korean families reveals dominance of the mutant allele. Hum Genet 83(2):119-21, 1989. PMID: 2777251.
153. Fang BL, Guo YF, Luo HY. [35S sulfate incorporation in cultured normal human skin fibroblasts and normal amniotic fluid cells]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 8(3):223-5, 1986. PMID: 2946465.
154. Fang BL, Shi HP, Luo HY. [Diagnosis and classification of mucopolysaccharidoses using the 35S-sulfate incorporation test]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 8(3):226-9, 1986. PMID: 2946466.
155. Fang BL, Shi HP, Luo HY. Diagnosis and classification of mucopolysaccharidoses using 35S-sulfate incorporation. Proc Chin Acad Med Sci Peking Union Med Coll 1(2):116-9, 1986. PMID: 3124094.
156. Fang BL, Guo YF, Luo HY. 35S-sulfate incorporation in cultured normal human skin fibroblasts and amniotic fluid cells. Proc Chin Acad Med Sci Peking Union Med Coll 1(2):120-2, 1986. PMID: 3432235.
157. Shi HP, Zhang GX, Guo YF, Fang BL, Zhang WM, Chen F, Luo HY. Laboratory diagnosis of lysosomal storage disease (Glycoproteinosis, Pompe's disease and Gaucher disease). Zhongguo Yi Xue Ke Xue Yuan Xue Bao 7(6):475-7, 1985. PMID: 2940012.
158. Fang B, Lo WHY. Mucopolysaccharidoses. Med Abroad Mol Genet 4:169-172, 1984.
159. Nilsson MB, Robichaux J, Herynk MH, Cascone T, Le X, Elamin Y, Patel S, Zhang F, Xu L, Hu L, Diao L, Shen L, He J, Yu X, Nikolinakos P, Saintigny P, Fang B, Girard L, Wang J, Minna JD, Wistuba II, Heymach JV. Altered regulation of HIF-1α in naïve- and drug-resistant EGFR mutant NSCLC: implications for a VEGF-dependent phenotype. J Thorac Oncol. e-Pub 2020. PMID: 33309987.
160. Kawakami M, Mustachio LM, Chen Y, Chen Z, Liu X, Wei CH, Roszik J, Kittai AS, Danilov AV, Zhang X, Fang B, Wang J, Heymach JV, Tyutyunyk-Massey L, Freemantle SJ, Kurie JM, Liu X, Dmitrovsky E. A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis and Metastasis in Aneuploid Cancers. Mol Cancer Ther. e-Pub 2020. PMID: 33277443.
161. Yan X, Zhang X, Wang L, Zhang R, Pu X, Wu S, Li L, Tong P, Wang J, Meng Q, Jensen VB, Girard L, Minna JD, Roth JA, Swisher SG, Heymach JV, Fang B. Inhibition of thioredoxin/thioredoxin reductase induces synthetic lethality in lung cancers with compromised glutathione homeostasis. Cancer Res 79(1):125-132. e-Pub 2018. PMID: 30401714.

Invited Articles

1. Dai B, Fang B, Roth JA. RNAi-Induced Synthetic Lethality in Cancer Therapy. Cancer Biol Ther 8(23):2314-6, 2009. e-Pub 2009. PMID: 19949302.
2. Guo ZS, Li Q, Bartlett DL, Yang JY, Fang B. Gene transfer: the challenge of regulated gene expression. Trends Mol Med, 2008. PMID: 18692441.
3. Guo W, Fang B. Potentiation of oncolytic virotherapy with armed shRNA. Cancer Biol Ther 8(1). e-Pub 2009. PMID: 19127117.
4. Guo W, Fang B. Enhancing anti-cancer virotherapy with heat-shock protein-mediated immune response. Cancer Biol Ther 7(2):196-7. e-Pub 2008. PMID: 8347427.

Book Chapters

1. Fang B, Roth JA. Tumour-suppressor gene therapy. In: Viral Therapy of Cancer. 1. John Wiley & Sons, Ltd: Rochester, MN, 229-239, 2008.
2. Zhang L, Fang B. Oncogenes, Tumor Suppressor Genes and Apoptosis-Inducing Genes Utilized in Cancer Gene Therapy. In: Gene Therapy for Cancer: Cancer Drug Discovery and Development. 1st. Humana Press: Totowa, NJ, 173-184, 2007.
3. Fang B, Roth JA. Adenovirus-mediated cancer gene therapy. In: Gene Therapy for Cancer: Cancer Drug Discovery and Development. 1st. Humana Press: Totowa, NJ, 3-22, 2007.
4. Zhang L, Fang B. Gene therapy targeting receptor-mediated cell death to concers. In: Death Receptors in Cancer Therapy. Humana Press: Totowa, NJ, 339-354, 2005.